Aerie Pharmaceuticals

Aerie Pharmaceuticals (NASDAQ: AERI) is a publicly traded, clinical-stage pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with glaucoma and other diseases of the eye. Aerie's two lead product candidates are once-daily IOP-lowering therapies with novel mechanisms of action to treat patients with glaucoma or ocular hypertension.[1][2][3]

References

  1. Witkowski, Wallace (16 September 2015). "Aerie Pharma Shares Skyrocket On Glaucoma Drug Study Results". Fox Business.
  2. Beckerman, Josh. "Aerie Pharmaceuticals Shares Rise on Trial Results". Wall Street Journal.
  3. "Aerie Pharma shares battered as eye drug fails study". Reuters. 23 April 2015. Retrieved 7 January 2016.

External links

This article is issued from Wikipedia - version of the 9/22/2016. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.